Phathom Pharmaceuticals goes public [Reuters]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Reuters
Phathom Pharmaceuticals goes public - PE Hub Phathom Pharmaceuticals goes public Menlo Park, California-based NASDAQ Goldman Sachs, Jefferies Evercore ISI Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation Sahsen. PRESS RELEASE BUFFALO GROVE, Ill.–(BINESS WIRE)–Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has priced its initial public offering of 9,563,157 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $181.7 million. All of the common stock is being offered Phathom. In addition, Phathom has granted the underwriters a 30-day option to purchase up to
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $24.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024GlobeNewswire
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTPR Newswire
PHAT
Earnings
- 3/7/24 - Miss
PHAT
Sec Filings
- 4/12/24 - Form DEFA14A
- 4/12/24 - Form DEF
- 4/12/24 - Form ARS
- PHAT's page on the SEC website